Myriad Genetics to deliver six abstracts at AACR 2026

Myriad Genetics (MYGN) announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research, AACR, Annual Meeting 2026. “AACR is one of the premier forums for oncology research, and we are excited to share the depth of work underway across our MRD and hereditary cancer programs, including two podium presentations demonstrating the exceptional performance of Precise MRD, Myriad’s tumor-informed, ultrasensitive MRD assay,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics.